China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Stason Pharmaceuticals Inc.’s Purinethol (mercaptopurine). The drug, classified as a Category 2.2 chemical drug, is now approved for the treatment of children with acute lymphoblastic leukemia (ALL), acute non-lymphocytic leukemia, and acute myeloid leukemia in the acute phase.
Drug Profile
The originator drug, Purinethol, is not yet available in China. However, seven local manufacturers, including China Resources Double-Crane, have secured marketing approvals for their generic versions. The company licensed the intellectual property rights to the drug from Beijing Children’s Hospital, Capital Medical University in March 2022.
Therapeutic Indications
The approved generic drug can be used to treat a range of leukemia conditions in children, providing a new treatment option for patients with acute lymphoblastic leukemia, acute non-lymphocytic leukemia, and acute myeloid leukemia.-Fineline Info & Tech
